ID
16710
Description
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Lien
https://clinicaltrials.gov/ct2/show/NCT00373425
Mots-clés
Versions (2)
- 01/08/2016 01/08/2016 -
- 27/09/2016 27/09/2016 -
Téléchargé le
1 août 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Prevention and Treatment of Skin, Hair and Nail Reactions, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Description
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Description
Record all topical creams, gels, oral or IV medications, and/or other interventions used to prevent and treat skin, hair and nail reactions (includes rash, skin fissures, nail and hair changes, etc) due to study drug administration. Moisturizers and sunscreens used to prevent and treat skin reactions should be recorded on the Moisturizers and Sunscreens CRF page.
Type de données
text
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C0221743
- UMLS CUI [2,1]
- C0087111
- UMLS CUI [2,2]
- C0018500
- UMLS CUI [3,1]
- C0087111
- UMLS CUI [3,2]
- C0234909
Description
Indication Prophylaxis
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C3146298
- UMLS CUI [1,2]
- C0199176
Description
Drug Administration Route
Type de données
integer
Alias
- UMLS CUI [1]
- C0013153
Description
Drug Administration Route
Type de données
text
Alias
- UMLS CUI [1]
- C0013153
Description
Specific Indication should be reported on the Adverse Event (Including Baseline Signs/Symptoms) CRF page, unless the intervention was given as a prophylaxis.
Type de données
integer
Alias
- UMLS CUI [1]
- C3146298
Description
Indication
Type de données
text
Alias
- UMLS CUI [1]
- C3146298
Description
Date Started
Type de données
date
Alias
- UMLS CUI [1]
- C3173309
Description
Date Stopped
Type de données
date
Alias
- UMLS CUI [1]
- C1531784
Description
Date Stopped
Type de données
boolean
Alias
- UMLS CUI [1]
- C1531784
Similar models
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0199176 (UMLS CUI [1,2])